340B ceiling price

340B Ceiling Price Explained: Formula, Rules & Errors

November 12, 2026•6 min read

A pharmacy invoice should not create a guessing game. When a charge differs from the expected figure, teams may spend hours comparing purchase records, package details, and pricing updates. Understanding the 340B ceiling price helps them investigate those differences with confidence.

The HRSA ceiling price is not a flat 340B discount percentage for every medicine. It is a drug-specific maximum calculated under federal law, and its underlying figures can change quarterly. Knowing the formula and where to verify it helps lean pharmacy teams review purchases more effectively.

What is the 340B Ceiling Price?

The 340B ceiling price is the maximum amount a manufacturer may charge a covered entity for a covered outpatient drug. Section 340B of the Public Health Service Act establishes this requirement. The Health Resources and Services Administration (HRSA) administers the program and provides ceiling-price information through the 340B Office of Pharmacy Affairs Information System (OPAIS).

For each covered outpatient drug, the calculation uses the Average Manufacturer Price (AMP) and Unit Rebate Amount (URA). Manufacturers calculate it quarterly using the preceding calendar quarter’s AMP for the smallest unit of measure, minus the URA. HRSA publishes the result to two decimal places, while the calculation uses six.

In practical terms, the HRSA ceiling price is a cap. It is not a promise that every covered entity will pay exactly that amount. A covered entity may obtain a lower price through a negotiated arrangement, such as a sub-ceiling price. The applicable purchasing terms and product details still matter.

340B Ceiling Price: How Does the 340B Pricing Formula Work?

The basic 340B pricing formula is straightforward. Here is the 340B ceiling price formula:

340B ceiling price = AMP − URA

Here is what each part means:

  • Average Manufacturer Price (AMP): The average price paid to the manufacturer by wholesalers for drugs distributed to retail community pharmacies, subject to the statutory and regulatory definition. For the ceiling-price calculation, the relevant AMP is reported for the smallest unit of measure.

  • Unit Rebate Amount (URA): The per-unit Medicaid rebate amount calculated under the Medicaid Drug Rebate Program. The applicable calculation depends on the drug’s classification and statutory rules.

The formula produces a per-unit ceiling price. For a package or order, teams must also account for the National Drug Code (NDC), package size, and case pack size. HRSA’s package-adjusted price applies the raw ceiling price to those quantities.

A simple 340B price calculation example

Here is an example of a 340B price calculation.

Suppose a covered outpatient drug has an illustrative AMP of $100.00 per smallest unit and a URA of $25.00 per unit. The calculation using the 340B pricing formula is:

$100.00 − $25.00 = $75.00 per unit

In this simplified example, $75.00 is the calculated 340B ceiling price per unit before considering package and case quantities. If the package contains 10 billing units and the case contains 2 packages, the illustrative package-adjusted amount would be $75.00 × 10 × 2 = $1,500.00.

These are illustrative figures, not actual prices. Real calculations use reported data, the applicable URA, the drug’s NDC and unit definitions, and HRSA’s rounding rules. Always use current authorized pricing data.

Why Might Your Invoice Not Match the 340B Ceiling Price?

A difference between a 340B ceiling price figure and an invoice does not automatically indicate an overcharge. Confirm that the drug, NDC, unit, package size, and quarter match, then review the purchasing terms.

Common reasons for a difference include:

  • Package and case quantities: The HRSA ceiling price is calculated at the unit level. The package-adjusted price incorporates package size and case pack size, so the two figures are not interchangeable.

  • Sub-ceiling pricing: A covered entity may purchase a drug below the statutory ceiling price through negotiated pricing or a purchasing arrangement.

  • Quarterly updates: AMP and URA data can change, which means the applicable ceiling price can change between quarters. A prior-quarter price may not be the right comparison for a current purchase.

  • Rounding: HRSA calculates the ceiling price to six decimal places and publishes it rounded to two decimal places. Small differences can appear when figures are rounded or extended across multiple units.

  • New-drug estimates or corrected data: Federal rules address estimated ceiling prices for new drugs before AMP is available and later price corrections. If a manufacturer determines that an overcharge occurred, applicable repayment or credit procedures may apply.

If a discrepancy remains, document the NDC, purchase date, quantity, invoice price, relevant ceiling-price data, and communications. Follow your organization’s process for raising a potential pricing issue.

Is There a Standard 340B Discount Percentage?

There is no single 340B discount percentage for every drug. The ceiling price uses AMP and URA, which depend on the product and applicable statutory rules. Therefore, the difference between commercial and 340B pricing varies by drug and quarter.

A claim that 340B always saves a fixed percentage is misleading. Review the actual price for the drug and NDC, compare it with the right benchmark, and confirm the entity’s eligibility and purchasing conditions.

Why Orphan Drug Pricing Needs an Additional Review

For certain hospitals, the 340B ceiling price calculation is only part of the picture. Under Section 340B(e), the orphan drug exclusion applies to specified hospital categories and drugs designated for rare diseases or conditions. Those drugs are not automatically subject to the standard ceiling-price requirement for affected entities, although manufacturers may choose to offer 340B pricing.

This matters to Critical Access Hospitals (CAHs), Rural Referral Centers (RRCs), and Sole Community Hospitals (SCHs). Participation in 340B does not mean every orphan drug is discounted. Teams should check entity type, drug designation, manufacturer policy, and current pricing status.

Manufacturer-discretionary pricing can change between periods. For hospitals managing high-cost therapies with limited staff, drug-by-drug tracking helps prevent missed opportunities and incorrect assumptions.

A Quarterly Checklist for 340B Pricing Reviews

Use a repeatable quarterly review to spot unusual charges and keep records organized:

  • Confirm the covered entity’s current 340B status and the locations or pharmacies involved in the purchase.

  • Match the drug name and 11-digit NDC on the invoice to the pricing record.

  • Check the applicable quarter and compare the unit-level ceiling price with the correct package-adjusted amount.

  • Review AMP, URA, package size, case pack size, and rounding where the data are available to your authorized users.

  • Identify any negotiated sub-ceiling pricing or other purchasing terms that explain a lower invoice amount.

  • For orphan drugs, verify the hospital category, FDA orphan designation, and current manufacturer-discretionary pricing status.

  • Record unresolved differences and follow up with the appropriate wholesaler, manufacturer, or internal 340B contact.

HRSA’s OPAIS pricing resources are the authoritative starting point for authorized users checking ceiling-price information. Keep supporting purchase and reconciliation records, so your team can explain how it reached its conclusion.

Turn 340B Pricing Data Into Better Orphan Drug Oversight

Understanding the 340B ceiling price supports purchasing decisions, budget planning, and savings reviews. Orphan drug pricing adds complexity because manufacturer decisions may sit outside the standard ceiling-price requirement for certain hospitals.

340B Orphan Drug Solutions supports hospitals, including CAHs, RRCs, and SCHs, with tailored drug lists, split-billing integration, and quarterly manufacturer-pricing updates. This helps pharmacy and finance teams reduce manual research and work from current information.

If your team spends hours checking orphan drug designations and manufacturer pricing, contact 340B Orphan Drug Solutions to discuss a tailored review of your facility’s orphan drug program.

Lisa Nezneski
I work exclusively with the four facility types the 2015 PhRMA v. HHS ruling made eligible for orphan drug pricing: Sole Community Hospitals (SCH), Critical Access Hospitals (CAH), Rural Referral Centers (RRC), and Free-Standing Cancer Centers (CAN). Twelve years. One lane. Every dollar recovered is a dollar you already paid out.
Back to Blog